Treatment with crizotinib has shown efficacy in a variety of ALK mutant and rearranged tumors including non‐small‐cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, and neuroblastoma,8, 9, 10 and now, there is emerging evidence of the effectiveness of ALK inhibitors in the treatment of tumors with ALK overexpression without mutation or fusion.11, 12. This evidence concerns the gene ALK and non-small cell lung carcinoma.